Article

Antibody-mediated co-delivery of programmable drug combinations

2024-10-30

Abstract excerpt

<title>Abstract</title> <p>Drug combinations often fail in clinic due to poor disease site tropism and additive toxicities1,2. Targeted delivery by antibody-drug conjugates (ADCs) reduces toxicity for single chemotherapeutic payloads3. Multi-payload ADCs for combination therapy are limited to two chemotherapeutics at fixed ratio due to a lack of efficient linker-payload chemistry and an incomplete understanding o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ba64ab64-afd1-519d-b935-f52494488aa9
DOI: 10.21203/rs.3.rs-5181233/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antibody-mediated co-delivery of programmable drug combinationsDOI 10.21203/rs.3.rs-5181233/v1Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.Semantic proximity Read

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Precision Nanotherapy for p53-Mutant Cancer Using Modular Triple-LNP DeliverySemantic proximity Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design PerspectiveSemantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerSemantic proximity Read

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read

Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology.Semantic proximity Read

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.Semantic proximity Read